GoldenGolden
Advanced Search
BioCardia

BioCardia

BioCardia is a biotechnology company making clinical stage regenerative medicine for cardiovascular diseases.

BioCardia is a clinical-stage regenerative medicine company. The company's mission is to bring to market comprehensive cell therapy solutions for the treatment of cardiovascular diseases with large unmet medical needs.

Its lead therapeutic candidate is the investigational CardiAMP™ Cell Therapy System, which provides an autologous bone marrow derived cell therapy (using a patient's own cells) for the treatment of two clinical indications, heart failure that develops after a heart attack and chronic myocardial ischemia.

BioCardia's second therapeutic platform, the CardiALLO™ Cell Therapy System, is an investigational culture expanded bone marrow derived allogenic or “off the shelf” cell therapy using neurokinin-1 receptor positive mesenchymal stem cells for the treatment of cardiac and pulmonary disease.

BioCardia has taken a new approach to addressing heart failure by introducing patient screening and efficient delivery to stem cell therapy, the company aims to increase the likelihood of treatment success, allowing more patients to return back to normal and the things they used to love.

Timeline

2002
BioCardia was founded.

Patents

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

BioCardia and CellProThera Partner for Clinical Trial and Marketing in Singapore of Early Stem Cell Therapy for Patients Following Myocardial Infarction

Business Wire

Web

BioCardia brings on clinical affairs VP to move regenerative heart therapy through phase 3 | FierceBiotech

Conor Hale

Web

BioCardia Developing Comprehensive Approach to Treat Heart Failure

Omar Ford

Web

Preliminary Results From BioCardia's Phase III Pivotal CardiAMP Heart Failure Trial Reported In Circulation Research Journal

BioCardia, Inc.

Web

Documentaries, videos and podcasts

Title
Date
Link

BioCardia Morph Deflectable Guide Catheter System - Training Video

February 2, 2017

Helix Transendocardial Delivery System

July 19, 2017

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
May 5, 2020
BioSpace
Plans IND Submission for Same Cells to Treat COVID-19 Induced Acute Respiratory Distress Syndrome

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.